MX2024009485A - Vacunas terapeuticas anti-alfa-sinucleina. - Google Patents
Vacunas terapeuticas anti-alfa-sinucleina.Info
- Publication number
- MX2024009485A MX2024009485A MX2024009485A MX2024009485A MX2024009485A MX 2024009485 A MX2024009485 A MX 2024009485A MX 2024009485 A MX2024009485 A MX 2024009485A MX 2024009485 A MX2024009485 A MX 2024009485A MX 2024009485 A MX2024009485 A MX 2024009485A
- Authority
- MX
- Mexico
- Prior art keywords
- present
- defined above
- peptide antigen
- synuclein
- alpha
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22156006 | 2022-02-09 | ||
| EP22156007 | 2022-02-09 | ||
| PCT/EP2023/053259 WO2023152260A1 (en) | 2022-02-09 | 2023-02-09 | Anti-alpha-synuclein therapeutic vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024009485A true MX2024009485A (es) | 2024-08-14 |
Family
ID=85175955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024009485A MX2024009485A (es) | 2022-02-09 | 2023-02-09 | Vacunas terapeuticas anti-alfa-sinucleina. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250152684A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4475878A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025506472A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240147981A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023219059A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3248093A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2024002370A1 (cg-RX-API-DMAC7.html) |
| CR (1) | CR20240371A (cg-RX-API-DMAC7.html) |
| IL (1) | IL314865A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024009485A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023152260A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250135293A (ko) * | 2023-01-26 | 2025-09-12 | 에이씨 이뮨 에스에이 | 리포좀 구조체 |
| WO2025109524A1 (en) | 2023-11-22 | 2025-05-30 | Ac Immune Sa | Assays and methods for assessing vaccine preparations |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050203010A1 (en) | 2003-11-14 | 2005-09-15 | Atgen Co., Ltd. | Novel peptides conferring environmental stress resistance and fusion proteins including said peptides |
| AT506535B1 (de) | 2008-02-22 | 2010-04-15 | Affiris Forschungs & Entwicklungs Gmbh | Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden |
| AT508638B1 (de) | 2009-08-21 | 2011-08-15 | Affiris Ag | Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien |
| EP2659907A1 (en) * | 2012-05-01 | 2013-11-06 | Affiris AG | Compositions |
| WO2013173827A2 (en) * | 2012-05-18 | 2013-11-21 | Board Of Regents Of The University Of Nebraska | Methods and compositions for inhibiting diseases of the central nervous system |
| CA3003943A1 (en) | 2015-11-03 | 2017-05-11 | Affiris Ag | Method for vaccination against a self-antigen in a human patient |
| TW202333768A (zh) * | 2017-10-25 | 2023-09-01 | 美商健生醫藥公司 | Tau胜肽之組成物及其用途 |
| MA52180A (fr) * | 2018-04-10 | 2021-02-17 | Ac Immune Sa | Vaccins thérapeutiques anti-abêta |
| JP7898188B2 (ja) * | 2020-08-04 | 2026-07-31 | エイシー イミューン ソシエテ アノニム | 免疫原性化合物 |
-
2023
- 2023-02-09 IL IL314865A patent/IL314865A/en unknown
- 2023-02-09 KR KR1020247025028A patent/KR20240147981A/ko active Pending
- 2023-02-09 EP EP23703593.6A patent/EP4475878A1/en active Pending
- 2023-02-09 JP JP2024547294A patent/JP2025506472A/ja active Pending
- 2023-02-09 AU AU2023219059A patent/AU2023219059A1/en active Pending
- 2023-02-09 CR CR20240371A patent/CR20240371A/es unknown
- 2023-02-09 CA CA3248093A patent/CA3248093A1/en active Pending
- 2023-02-09 MX MX2024009485A patent/MX2024009485A/es unknown
- 2023-02-09 US US18/836,298 patent/US20250152684A1/en active Pending
- 2023-02-09 WO PCT/EP2023/053259 patent/WO2023152260A1/en not_active Ceased
-
2024
- 2024-08-07 CL CL2024002370A patent/CL2024002370A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20250152684A1 (en) | 2025-05-15 |
| IL314865A (en) | 2024-10-01 |
| EP4475878A1 (en) | 2024-12-18 |
| CR20240371A (es) | 2024-10-16 |
| CA3248093A1 (en) | 2023-08-17 |
| WO2023152260A1 (en) | 2023-08-17 |
| KR20240147981A (ko) | 2024-10-10 |
| JP2025506472A (ja) | 2025-03-11 |
| AU2023219059A1 (en) | 2024-07-25 |
| CL2024002370A1 (es) | 2024-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024002370A1 (es) | Vacunas terapeuticas anti-alfa-sinucleína. | |
| AR110887A2 (es) | Región constante de anticuerpo mutante | |
| CY1105597T1 (el) | Ανοσοθεραπευτικες μεθοδοι χρησιμοποιωντας επιτοπους των wt-1 και gata-1 | |
| CA2489227A1 (en) | Hla-a24-restricted cancer antigen peptides | |
| PE20231212A1 (es) | Polipeptidos variantes proteoliticamente estables de u1-agatoxina-ta1b para el control de plagas | |
| DK1531791T3 (da) | Forebyggelse og begrænsning af iskæmi | |
| MX377692B (es) | Peptidos anti-inflamatorios y usos de los mismos. | |
| RU2009119597A (ru) | Новые белки н5, кодирующие их молекулы нуклеиновых кислот и векторы, и их применение в медицине | |
| AR123187A1 (es) | Vacuna de múltiples epítopos para el tratamiento de la enfermedad de alzheimer | |
| AR120891A1 (es) | Proteína rsv f mutante y su uso | |
| ATE527364T1 (de) | Polypeptide erhaltend eine modifizierte menschliche serum-albumin sekretions-pre-sequenz mit erhöhtem ausscheidungsertrag | |
| MX2023005770A (es) | Tetrapeptido y composiciones que comprenden tetrapeptidos. | |
| CO2021017664A2 (es) | Péptidos | |
| RU2015113348A (ru) | Проникающие в клетки пептиды, связывающие интерферон-регулирующий фактор 5 | |
| CU24746B1 (es) | Apirasas humanas, solubilizadas y modificadas útiles para prevenir y tratar el daño tisular | |
| PE96899A1 (es) | Genes aislados de proteinas de membranas de mamiferos; reactivos relacionados | |
| PE20231952A1 (es) | Compuestos y su uso en el tratamiento de trastornos mediados por receptores de taquicinina | |
| MX2023001483A (es) | Compuestos inmunogenicos. | |
| MXPA06014393A (es) | Peptidos oligomericos y su uso para el tratamiento de infecciones por vih. | |
| ES2548677T3 (es) | Vacunas recombinantes contra copépodos caligidos (piojos de mar) y secuencias de antígeno de las mismas | |
| NZ592340A (en) | A method for making a virus vaccine compising Replikin peptides | |
| ATE509025T1 (de) | ßMIT MHC-KLASSE-I-PEPTIDEPITOPEN KOVALENT VERKN PFTES MEMBRANVERANKERTES BETA2-MIKROGLOBULINß | |
| ES2143996T3 (es) | Antigenos peptidicos del hcv y procedimiento para la determinacion del hcv. | |
| MX2023014318A (es) | Metodos de tratamiento mejorados utilizando peptidos inmunogenicos. | |
| AR069047A1 (es) | Peptidos y lipopeptidos sinteticos antigenicos derivados de mycobacterium avium subsp. paratuberculosis |